Home / Intelligence / Case Studies / Cross-Functional Launch Strategy Alignment Workshop
Trinity organized a full day on-site workshop to bring together key cross functional client teams to align on a final launch strategy for their mNSCLC asset in Japan.
Geographic Scope: 
Client Situation:
The client wanted to build alignment on the launch pricing & market access assumptions for their asset in metastatic non-small cell lung cancer (mNSCLC) and metastatic colorectal cancer (mCRC) in Japan, including consideration of all forecasting assumptions and pricing and market access (P&MA) risks.
Trinity’s Solution:
Trinity conducted targeted secondary research to determine the existing mNSCLC and mCRC treatment paradigm, as well as oncology regulatory landscape in Japan.
Trinity then organized a full-day day workshop at the client’s local office in Japan to enable cross functional client teams to collaborate on forecasting assumptions and optimal launch strategies.
Deliverables
- Case studies of oncology analogues and recent pricing outcomes in JPN
- In-depth policy review of JPN’s new health technology assessment (HTA) process
- Final report with detailed summary of workshop outputs
- Final launch pricing and commercial strategy
Project Outcomes & Impact:
The workshop generated the opportunity for the client’s local team to deliver nuanced local expertise and strategic insights to the global team to ensure that the updated launch forecast model included realistic access assumptions.
Related Intelligence
Webinars
The NRDL Conundrum: Balancing Between Access and Pricing for Innovation
May 21, 2025 | 1:00 – 1:45 PM ET
What key insights emerged from the 2024 China National Reimbursement Drug List (NRDL) negotiations and how can they inform strategic go-to-market planning for innovative therapies? In the 2024 NRDL negotiations, only 28% of submitted products passed expert review, significantly raising the bar for entering pricing negotiations.
Sign Up Now
White Papers
Predicting Winners: AI-Powered Portfolio Management
Can artificial intelligence and machine learning (AIML) be used to support portfolio decision-making across the life sciences industry? In this installment of our Industry Impact Series, we find that not only can the latest AIML techniques identify the drivers of success and failure in commercialization, but Trinity Life Sciences’ AI algorithm accurately predicts revenue outcomes for […]
Read More
Webinars
Launch & Learn: Trinity Launch Accelerator
Available On Demand
Today’s launch environment is fraught with greater complexity, lack of standardization and executional inefficiency. Join us for a virtual lunch and learn where experts share how Launch Accelerator enables teams to overcome launch barriers with a simple launch readiness and management process.
Watch Now